EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial

Xueli Bai iD, Xiang Li, Yiwen Chen, Xiaozhen Zhang iD, Xiaochen Zhang iD, Qi Zhang, Tao Ma, Yiqi Yu, Huan Luo, Jiaqi Yang, Lan Jia, Guoliang Qiao und 11 weitere

Journal of Clinical Oncology · 02.11.2026

DOI: 10.1200/jco-26-01393 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 02.11.2026. Verfasst von Xueli Bai und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit nennt 21 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The optimal treatment strategy for patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) remains undefined. We evaluated whether the addition of programmed cell death protein 1 blockade to modified FOLFIRINOX improves outcomes compared with modified FOLFIRINOX alone.

Methods

In this open-label, randomized phase II trial, patients with histologically confirmed BRPC or LAPC were randomly assigned (1:1) to receive modified FOLFIRINOX plus toripalimab (immunochemotherapy) or modified FOLFIRINOX alone (chemotherapy). Treatment response was assessed every 2 months, and surgical eligibility was determined by a multidisciplinary team. The primary end point was event-free survival (EFS) in the intention-to-treat population.

Results

Between April 2019 and March 2025, 392 patients were randomly assigned to immunochemotherapy (n = 196) or chemotherapy (n = 196). After a median follow-up of 39.6 months, immunochemotherapy significantly improved EFS compared with chemotherapy (median, 11.1 v 9.6 months; hazard ratio [HR], 0.74 [95% CI, 0.60 to 0.92]; P = .007). The median overall survival (OS) was 20.6 versus 17.1 months (HR, 0.81; 95% CI, 0.63 to 1.03). Objective response rates were 30.1% (59/196) and 18.9% (37/196), respectively. Tumor resection rates were 42.3% (83/196) and 43.9% (86/196), and R0 resection rates were 84.1% (69/82) and 74.7% (62/83), respectively. Prespecified subgroup analyses suggested improved EFS and OS in BRPC but not LAPC. Grade 3 or higher adverse events occurred in 47.9% (93/194) and 49.2% (96/195) of patients receiving immunochemotherapy and chemotherapy, respectively. Grade III or higher postoperative complications occurred in 30.1% (25/83) and 25.6% (22/86) of resected patients.

Conclusion

The addition of PD-1 blockade to modified FOLFIRINOX significantly improved EFS without increasing treatment-related toxicity or surgical morbidity in patients with BRPC or LAPC.

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, China.
  • MOE Joint International Research Laboratory of Pancreatic Diseases, Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, China.
  • Cancer Center, Zhejiang University, Hangzhou, China.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Xueli Bai, Xiaozhen Zhang, Xiaochen Zhang, Wenbo Xiao, Tian'an Jiang, Tingbo Liang

Zitieren

APA

Bai, X., Li, X., Chen, Y., Zhang, X., Zhang, X., Zhang, Q., Ma, T., Yu, Y., Luo, H., Yang, J., Jia, L., Qiao, G., Gao, S., Zhang, M., Shen, Y., Wu, J., Yu, J., Que, R., Sun, K., …, & Liang, T. (2026). Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01393

Vancouver

Bai X, Li X, Chen Y, Zhang X, Zhang X, Zhang Q, et al. Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01393

BibTeX
@article{Bai2026,
  author = {Bai, Xueli and Li, Xiang and Chen, Yiwen and Zhang, Xiaozhen and Zhang, Xiaochen and Zhang, Qi and Ma, Tao and Yu, Yiqi and Luo, Huan and Yang, Jiaqi and Jia, Lan and Qiao, Guoliang and Gao, Shunliang and Zhang, Min and Shen, Yan and Wu, Jian and Yu, Jun and Que, Risheng and Sun, Ke and Xiao, Wenbo and Xue, Xing and Jiang, Tian'an and Liang, Tingbo},
  title = {Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-01393}
}
Kostenlos starten →